Phase 2 Study of WGI-0301 for Advanced HCC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have previously received PD-1 / PD-L1 immune checkpoint inhibitors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznaniem raka wątroby (histologicznie, cytologicznie lub klinicznie)
- •Zaawansowany rak wątroby niezdatny do operacji i transplantacji
- •Wcześniejsze leczenie nie przyniosło rezultatu lub pacjent go nie toleruje
- •Po immunoterapii - potwierdzony postęp choroby lub brak tolerancji leczenia
- •Ogólny stan zdrowia pozwalający na leczenie (ECOG 0 lub 1)
- •Co najmniej jeden widoczny guz do zmierzenia na zdjęciach
- •Zdolność do podjęcia leczenia Sorafenibem
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (9)
China Pharmaceutical University, Shanghai Gobroad Cancer Hospital
Shanghai, China
Hunan Cancer Hospital
Changsha, China
West China Hospital Sichuan University
Chengdu, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Jiangxi Cancer Hospital
Nanchang, China
Tongji Hospital Tongji Medical College of HUST
Wuhan, China
Prince of Wales Hospital
Hong Kong, Hong Kong
Trial contact
Angela Men, MD., Ph.D
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/12/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.